Capricor 肌肉萎缩症疗法第二次被美国监管机构拒绝
Capricor’s therapy for a deadly form of muscular dystrophy was rejected for the second time by US regulators, a blow for the company and those pushin...
AI 导读
Capricor 针对一种致命性肌肉萎缩症的疗法第二次被美国监管机构拒绝,这对公司和推动罕见病治疗更广泛获取的人士都是一次打击。